Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
Abstract Recent discoveries in molecular diagnostics and drug treatments have improved the treatment of patients with advanced (inoperable) non-squamous non-small cell lung cancer (NSCLC) from solely platinum-based chemotherapy to more personalized treatment, including targeted therapies and immunotherapies. However, these improvements come at considerable costs, highlighting the need to assess their cost-effectiveness in order to optimize lung cancer care. Traditionally, cost-effectiveness models for the evaluation of new lung cancer treatments were based on the findings of the randomized con... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Scientific Reports ; volume 13, issue 1 ; ISSN 2045-2322 |
Verlag/Hrsg.: |
Springer Science and Business Media LLC
|
Schlagwörter: | Multidisciplinary |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27236754 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1038/s41598-023-29286-5 |